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Abstract
Background: We sought to examine the detection rate of cancer cells in peripheral blood (PBL) and in
bone marrow (BM) using an established 7-gene marker panel and evaluated whether there were any
definable associations of any individual gene with traditional predictors of prognosis.
Methods: Patients with T1-T3 primary breast cancer were enrolled into a prospective, multi-institutional
cohort study. In this interim analysis 215 PBL and 177 BM samples were analyzed by multimarker, real-
time RT-PCR analysis designed to detect circulating and disseminated breast cancer cells.
Results: At a threshold of three standard deviations from the mean expression level of normal controls,
63% (136/215) of PBL and 11% (19/177) of BM samples were positive for at least one cancer-associated
marker. Marker positivity in PBL demonstrated a statistically significant association with grade II-III (vs.
grade I; p = 0.0083). Overexpression of the mammaglobin (mam) gene alone had a statistically significant
association with high tumor grade (p = 0.0315), and showed a trend towards ER-negative tumors and a
high risk category. There was no association between marker positivity in PBL and the pathologic (H&E)
and/or molecular (RT-PCR) status of the axillary lymph nodes (ALN).
Conclusion: This study suggests that molecular detection of circulating cancer cells in PBL detected by
RT-PCR is associated with high tumor grade and specifically that overexpression of the mam gene in PBL
may be a poor prognostic indicator. There was no statistically significant association between
overexpression of cancer-associated genes in PBL and ALN status, supporting the concept of two
potentially separate metastatic pathways.
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There is a significant amount of ongoing work aimed at
defining the role of circulating tumor cells (CTC) in
peripheral blood (PBL) and disseminated tumor cells
(DTC) in bone marrow (BM) of breast cancer patients.
However, due to a variety of available tumor cell detection
methods and use of different gene-markers, recently pub-
lished studies show a wide range of results that are often
contradictory and difficult to compare to one another.
The main tumor cell detection methods have been immu-
nocytochemistry (ICC) with cytokeratin-specific antibod-
ies [1-11] and RT-PCR analysis based on overexpression of
cancer-associated gene-markers [4,6,12-29]. PCR method-
ology for detection of breast cancer has most frequently
employed mammaglobin (mam) and cytokeratin 19
(CK19) genes. Some studies have also used a new Cell-
Search System technology that employs immunomagnetic
separation of epithelial cells based upon expression of
cytokeratins or EpCAM and visualization of the tumor
cells by immunoflorescent microscopy [30].
Our laboratory has extensive experience in detection of
cancer cells using multi-marker real-time RT-PCR meth-
odology [31-35]. To address the clinical relevance of
molecular detection of occult breast cancer, we initiated a
multi-institutional prospective cohort study. The primary
objective of the study was to determine whether the
molecular detection of occult breast cancer by multi-
marker real-time RT-PCR in patients with pathology-neg-
ative axillary lymph nodes (ALN) is a clinically relevant
predictor of disease recurrence. An interim analysis of 489
patients enrolled in the study showed a statistically signif-
icant association between molecular detection of occult
breast cancer in the ALN and traditional predictors of poor
prognosis in subjects with pathology-negative ALN [33].
In addition, in a separate publication we show that the
sensitivity of sentinel lymph node (SLN) analysis to pre-
dict pathologic status of ALN was significantly increased
by the addition of molecular analysis [34].
There are several cancer-associated gene markers used in
the detection of breast cancer cells. Based on the heterog-
enous nature of the breast cancer, the multi-marker panel
approach has shown to increase the sensitivity of molecu-
lar assay to detect the presence of disseminated cancer
cells. However, the prognostic value of each individual
marker is not known and therefore the ultimate goal
would be to identify genes that are capable of differentiat-
ing patients with poor prognosis from the patients with a
more favorable prognosis. Having a tool to recognize the
subset of patients with unfavorable molecular characteris-
tics could potentially translate into a better clinical out-
come. In this interim analysis we examine the detection
rate of cancer cells in PBL and in BM using an established
7-gene marker panel and evaluated whether there were
any definable associations of any individual gene with the
traditional predictors of prognosis.
Methods
MIMS Trial Study Design
A prospective cohort study design was adopted where,
upon recruitment, eligible participants with Stage I, IIa, or
IIb breast cancer were requested to consent to tissue sam-
pling from axillary lymph nodes (ALN), sentinel nodes
(SLN), bone marrow (BM), and peripheral blood (PBL).
Tissue sampling was accomplished at the time of surgical
intervention. The study was carried out in compliance
with the Helsinki Declaration ethical principles in medi-
cal research involving human subjects. All specimens were
collected through the Medical University of South Caro-
lina Institutional Review Board for Human Research
approved protocols (HR 9551, HR 8374, HR 8903, HR
8432). Informed consent was obtained in accordance
with each participating center's Institutional Review
Board guidelines. The design, enrollment criteria, tissue
acquisition protocols, and determination of gene expres-
sion values for patients enrolled in the MIMS trial are
described in more detail in a separate publication [33].
The current study focuses on the subset of 215 patients
with PBL samples and the subset of 177 patients with BM
samples. Real-time RT-PCR analyses for cancer-associated
genes were performed on all specimens at the Central
Molecular Diagnostics Laboratory at the Medical Univer-
sity of South Carolina (MUSC). The Clinical Innovation
Group (TCIG, Charleston, SC) (later known as the Data
Coordination Unit (DCU) in the Department of Biostatis-
tics, Bioinformatics and Epidemiology at MUSC) served
as the coordinating center, and all study data were col-
lected, processed and analyzed at this central facility.
Blood and bone marrow samples from breast cancer 
subjects
Bone marrow aspirates were obtained from patient's left
and or right anterior or posterior iliac crests under
anesthesia at the time of operation. A 10 or 20 cc syringe
with a 16–18 gauge bone marrow aspirate needle was
used to aspirate 3–6 ml of bone marrow into a syringe and
then immediately transferred to a sterile EDTA vacutainer.
Peripheral blood samples were obtained before surgery or
following the induction of anesthesia. A total of 5–10 ml
of blood was drawn from a peripheral vein into a sterile
EDTA vacutainer. Blood and bone marrow samples were
then shipped at room temperature to the Central Molecu-
lar Diagnostics Laboratory at the MUSC for immediate
processing by Ficoll density gradient centrifugation
(Ficoll-Paque Plus; Amersham Biosciences). All the speci-
mens inside US arrived in 24 hours and international
shipments arrived in 48 hours. One mL of bone marrow
was used for Cytospin preparation and stained for ICC
analysis. These bone marrow samples were evaluated by aPage 2 of 11
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cytokeratin AE1/AE3. Please note that the specimen acqui-
sition protocol was amended after the initiation of the
MIMS trial and for that reason only a subset of patients
was included in this analysis.
Blood and bone marrow samples from control subjects 
without evidence of malignancy
In order to define baseline expression levels for the molec-
ular markers used in this study, PBL and BM samples from
control subjects were procured. Informed consent was
obtained for BM aspiration from 49 patients undergoing
orthopedic surgery at MUSC and for PBL drawn from 49
healthy volunteers. None of the control subjects had any
history or clinical evidence of malignancy. Four to six ml
of BM aspirate or 5–10 ml of PBL was transferred to an
EDTA vacutainer and sent to the Central Molecular Diag-
nostics Laboratory to be processed by Ficoll density gradi-
ent centrifugation and analyzed by real-time RT-PCR.
RNA isolation and cDNA synthesis
Buffy coats were obtained by Ficoll density gradient cen-
trifugation, and total cellular RNA was isolated using a
guanidinium thiocyanate-phenol-chloroform solution
(RNA STAT-60™; TEL-TEST, Friendswood, TX). Briefly,
cells were re-suspended in 1 ml of RNA STAT-60™. Total
RNA was isolated as per the manufacturer's instructions
with the exception that 1 μL of a 50 mg/mL solution of
glycogen (Sigma, St. Louis, MO) was added to the aque-
ous phase prior to addition of isopropanol. Glycogen was
used as a nucleic acid carrier to enhance RNA precipita-
tion. The RNA pellet was dissolved in 50 μl of 1x RNA
secure buffer (Ambion, Austin, TX). RNA was quantified
by spectrophotometry at 260 nm. cDNA was made from 5
μg of total RNA using 200 U of M-MLV reverse tran-
scriptase (Promega, Madison, WI) and 0.5 μg Oligo
(dT)12–16 in a reaction volume of 20 μl (10 min at 70°C,
50 min at 42°C, 15 min at 70°C).
Real-time RT-PCR
The real-time RT-PCR primers have been previously
reported [31,36,37]: mglo: F 5'-GCCGTGTGAACCATGT-
GACTTT, R 5'-CCAAATGCGGCATCTTCAAA; PDEF: F 5'-
AGTGCTCAAGGACATCGAGACG, R 5'-AGCCACTTCT-
GCACATTGCTG; mam: F 5'-CGGATGAAACTCTGAG-
CAATGT, R 5'-CTGCAGTTCTGTGAGCCAAAG; CK19: F
5'-CATGAAAGCTGCCTTGGAAGA, R 5'-TGATTCT-
GCCGCTCACTATCAG; muc1: F 5'-ACCATCCTAT-
GAGCGAGTACC, R 5'-ACCATCCTATGAGCGAGTACC;
PIP: F 5'-GCCAACAAAGCTCAGGACAAC, R 5'-GCAGT-
GACTTCGTCATTTGGAC; EpCAM: F 5'-CGCAGCTCAG-
GAAGAATGTG, R 5'-TGAAGTACACTGGCATTGACGA;
ErbB2: F 5'-CTGGTGACACAGCTTATGCCCT, R 5'-ATC-
CCCTTGGCAATCTGCA. Analyses were performed on a
PE Biosystems Gene Amp® 5700 Sequence Detection Sys-
tem (Foster City, CA). All reaction components were pur-
chased from PE Biosystems. The standard reaction volume
was 10 μl and contained 1X SYBR Green PCR Buffer; 3.5
mM MgCl2; 0.2 mM each of dATP, dCTP, and dGTP; 0.4
mM of dUTP; 0.25 U AmpliTaq Gold®; 0.1 U AmpErase®
UNG enzyme; 0.7 μl cDNA template; and 0.25 mM of
both forward and reverse primer. The initial step of PCR
was 2 min at 50°C for AmpErase® UNG activation, fol-
lowed by a 10-min hold at 95°C. Cycles (n = 40) con-
sisted of a 15 sec denaturation step at 95°C, followed by
a 1 min annealing/extension step at 60°C. The final step
was a 60°C incubation for 1 min. All reactions were per-
formed in triplicate. The cycle of threshold (Ct) analysis
was set at 0.5 relative fluorescence units.
Primary data analysis
Real-time RT-PCR data were quantified as Ct values that
are inversely related to the amount of starting template:
high Ct values correlate with low levels of gene expression,
whereas low Ct values correlate with high levels of gene
expression. Each gene was analyzed in triplicate. Results
were normalized to an internal control reference gene, β2-
microglobin, by subtracting the mean Ct value of β2-
microglobin from the mean Ct value of each respective gene
(ΔCt value). Samples for which Ct values for β2-microglobin
were equal or higher than 22 were considered to contain
inadequate RNA and were excluded from the analysis.
Approximately 10% of samples we rejected from the anal-
ysis based on this criterion. If the mean Ct value for a gene
of interest was higher or equal to 38, the gene expression
was considered to be undetectable. In order to define
baseline levels of gene expression and to define thresholds
for marker positivity, 49 specimens of PBL and 49 speci-
mens of BM obtained from patients with no evidence of
malignancy were analyzed. To be consistent with the pre-
vious molecular analyses of lymph nodes, threshold val-
ues for each individual marker were set at three standard
deviations from the mean ΔCt value in the control group.
A subject was considered to be positive for the molecular
analysis if at least one marker in the panel was above the
defined threshold. Data from real-time RT-PCR analyses
were compiled in a Microsoft Access database and submit-
ted to the DCU at MUSC for statistical analyses. The
molecular analysis was generated blinded to clinical out-
come and patients' clinicopathologic data.
Bone marrow cytopathology and cytokeratin ICC staining
Specimens were collected, washed in CytoLyt® (Cytyc,
Boston, MA) and then resuspended in PreservCyt®
(Cytyc). Two ThinPrep (TP) slides were prepared and
stained with Papanicolaou stain, and one slide was used
for immunocytochemistry (ICC). A monoclonal antibody
for cytokeratin (AE1/AE3) was used in conjunction with
an automated immunostaining system (DAKO Auto-
stainer, DAKO Cytomation, Carpeteria, CA) and a NexusPage 3 of 11
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Medical Systems Inc, Tuscon, AZ). Immunostaining was
performed with the avidin-biotin immunoperoxidase
(ABC-peroxidase) method of Hsu et al [38]. Briefly, the
slides were incubated with primary antibody for 30 min-
utes and then incubated with secondary biotinylated anti-
body for 4 minutes. To visualize the antibody, the TP was
treated with diaminobenzidine (0.05%) in 0.05 M Tris-
HCL buffer (pH 7.8) with 0.03% H2O2 for 6 minutes and
then washed in H2O. TP was counterstained with hema-
toxylin, dehydrated, cleared in xylene, and mounted in
Permount. The specimens were analyzed by a skilled
cytopathologist.
Statistical analysis
SAS Version 9.1 Software (SAS Institute Inc., SAS Campus
Drive, Cary, North Carolina) was used for the analysis of
pathological and molecular outcome. Chi-square analyses
were conducted to explore the association between pre-
defined baseline covariates that have been associated with
pathological outcome in prior studies and PBL and BM
RT-PCR positivity/negativity status. Pre-defined baseline
covariates were tumor size, histological grade, estrogen
receptor status, progesterone receptor status, her2neu sta-
tus, and St. Gallen risk category (minimal/low risk: tumor
size ≤ 1 cm, positive ER and/or PR status, grade I and age
≥ 35; intermediate risk: tumor size >1 or 2 cm, positive ER
and/or PR status, and grade I; and high risk: lymph node
positive, tumor size > 2 cm, negative ER and/or PR status,
grade II or III, or age <35) [39]. Statistical significance was
defined as p-values < 0.05.
Results
Demographic and clinicopathologic analysis
The distribution of the demographic and clinicopatho-
logic characteristics in Table 1 indicate that the subset of
patients with PBL analysis (n = 215) and the subset of
patients with BM analysis (n = 177) are representative of
the entire study group of 489 [33].
Precise quantitation of gene-marker expression in normal 
control bone marrow and peripheral blood samples
We have previously shown that the majority of known
breast cancer-associated genes have some background
expression in normal lymph nodes [31,36,37]. For this
study we selected seven breast cancer-associated genes
[mam, CEA, CK19, PIP, muc1, PSE, Erb (BM only) and
EpCAM (PBL only)] known to be over-expressed in meta-
static breast cancer compared to control lymph nodes
[31,36,37]. For this study, baseline gene expression was
precisely quantitated in 49 normal PBL samples and 49
normal BM samples by real-time RT-PCR (Figure 1A and
1B; horizontal lines indicate the ΔCt thresholds). To
obtain maximum specificity, a threshold value for marker
positivity, i.e. abnormal expression was set at three stand-
ard deviations from the mean ΔCt value for each gene. Out
of seven cancer-associated gene-markers used to detect
tumor cells in PBL and BM, CK19, muc1 and ErbB2 were
not informative due to the high expression in normal con-
trol samples.
Real-time RT-PCR analysis of gene expression in 
peripheral blood of breast cancer patients
Using the five-marker gene-panel (mam, PIP, CEA, PSE
and EpCAM) at the threshold of three standard deviations
above the mean expression level in normal control sam-
ples for each gene, 136 (63%) patients out of 215 were
positive for at least one marker. On an individual marker
basis (Table 2), the most frequently over-expressed mark-
ers were PSE (58/215; 27.0%) and CEA (51/215; 23.7%)
followed by PIP (36/215; 16.7%), mam (29/215; 13.5%)
and EpCAM (7/215; 3.3%). Marker positivity in PBL dem-
onstrated a statistically significant association with grade
II-III (vs. grade I; p = 0.0083; Table 3). Out of 136 RT-PCR
positive patients 97 patients (71%) were positive for one,
33 patients (24%) for two and six patients (4%) for three
markers. Interestingly, over-expression of PSE gene had
statistically significant association with ER-positive and
PR-positive tumors (p = 0.0123 and p = 0.0134, respec-
tively) and showed a trend towards pathology-negative
nodal status (31% vs. 19%; Table 3). However, overex-
pression of mam gene had statistically significant associa-
tion with high grade (p = 0.0315) and showed a trend
towards ER-negative tumors (22% vs. 11%) and a high
risk category (15% vs. 6%; Table 3). Interestingly, there
was no association between marker positivity in PBL and
either pathologic (H&E) status or molecular (multi-
marker qRT-PCR) status of axillary lymph nodes.
Real-time RT-PCR analysis of cancer-associated gene 
expression in bone marrow
Using a four-marker gene-panel (mam, PIP, CEA, and PSE)
at the threshold of three standard deviations above the
mean expression level in normal control samples for each
gene, 19 patients (11%) out of 177 were positive. All 19
were positive to one marker only. Marker positivity in
bone marrow had no statistically significant association
with any of the traditional prognostic indicators. Looking
at individual markers separately (Table 2), the most fre-
quently overexpressed marker was mam (7/177; 4.0%)
followed by PIP (5/177; 2.8%), PSE (5/177; 2.8%) and
CEA (2/177; 1.1%)
Comparison of molecular analysis of blood and bone 
marrow
To determine whether there was an association between
molecular analysis in PBL and molecular analysis in BM,
we performed Chi-Square and Fisher's Exact test on 138
patients that had results from both PBL and from BM
(Table 4). Comparison of the results using gene-panelPage 4 of 11
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however, the results of mam and PIP gene expression in
PBL had statistically significant association with the mam
and PIP gene expression in BM (p = 2.5E-04 and p =
0.0188, respectively).
Immunocytochemistry (ICC) versus RT-PCR in bone 
marrow
BM cytopathology assessment resulted in detection of no
abnormal or suspicious cells. Eighty three BM samples
were randomly selected for additional cytokeratin ICC
staining. Five out of 83 (6%) samples were positive by
ICC and two of these samples were also positive by RT-
PCR (one positive for mam and other for PIP). Ten
patients out of 83 (12%) that had inconclusive ICC results
were all RT-PCR negative (Table 5). Although there was
84% agreement (excluding inconclusive ICC results)
between 2 methodologies, this was mostly because of the
concordance of dual negative findings. Overall there was
no statistically significant association between ICC and
Table 1: Patient Demographic and Clinicopathologic Characteristics
Characteristic MIMS Trial study group (n = 489) Peripheral blood (n = 215) Bone marrow (n = 177)
Age
Mean (St. Dev.) 56.8 (11.4) 56.3 (10.9) 56.3 (10.8)
Range 26, 89 29, 84 30, 83
Race
Caucasian 421 (86.1%) 180 (83.7%) 157 (88.7%)
Black 61 (12.5%) 31 (14.4%) 18 (10.2%)
Other 7 (1.5%) 4 (1.9%) 2 (1.1%)
Primary Tumor
T1 334 (68.3%) 146 (67.9%) 117 (66.1%)
T2 145 (29.7%) 63 (29.3%) 52 (29.4%)
T3 10 (2.1%) 6 (2.8%) 8 (4.5%)
Histologic Grade
I 133 (27.2%) 63 (29.3%) 53 (29.9%)
II 195 (39.9%) 89 (41.4%) 66 (37.3%)
III 136 (27.8%) 54 (25.1%) 49 (27.7%)
Nodal Metastases (H&E)
N0 344 (70.4%) 150 (69.8%) 127 (71.8%)
N1 145 (29.7%) 64 (29.8%) 49 (27.7%)
Nodal Metastases (PCR)
N0 251 (51.3%) 116 (54.0%) 94 (53.1%)
N1 238 (48.7%) 96 (44.7%) 80 (45.2%)
Clinical Stage:
I 267 (54.6%) 120 (55.8%) 97 (54.8%)
IIA 138 (28.2%) 55 (25.6%) 47 (26.6%)
IIB 69 (14.1%) 33 (15.4%) 25 (14.1%)
IIIA 11 (2.3%) 7 (3.3%) 8 (4.5%)
IIIB 2 (0.4%) 0 (0%) 0 (0%)
IV 2 (0.4%) 0 (0%) 0 (0%)
ER Status
ER-neg 107 (21.9%) 46 (21.4%) 42 (23.7%)
ER-pos 360 (73.6%) 154 (71.6%) 122 (68.9%)
PR Status
PR-neg 156 (31.9%) 67 (31.2%) 58 (32.8%)
PR-pos 284 (58.1%) 120 (55.8%) 85 (48.0%)
Her2neu Status
Her2neu-neg 218 (44.6%) 115 (53.5%) 91 (51.4%)
Her2neu-pos 89 (18.2%) 42 (19.5%) 30 (16.9%)
Histologic Type
Infiltrating Ductal 394 (80.6%) 167 (77.7%) 140 (79.1%)
Infiltrating Lobular 44 (9.0%) 18 (8.4%) 16 (9.0%)
Other 50 (10.2%) 30 (14.0%) 21 (11.9%)
Risk Category
Low Risk 53 (10.8%) 23 (10.7%) 16 (9.0%)
Intermediate Risk 50 (10.2%) 11 (5.1%) 13 (7.3%)
High Risk 386 (78.9%) 181 (84.2%) 148 (83.6%)Page 5 of 11
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Real-time RT-PCR analysis of cancer-associated gene expression in peripheral blood (A) and bone marrow (B) from breast cancer patients (filled triangle) d in norm l control blood and bone marrow samples (empty circles)Figure 1
Real-time RT-PCR analysis of cancer-associated gene expression in peripheral blood (A) and bone marrow (B) 
from breast cancer patients (filled triangle) and in normal control blood and bone marrow samples (empty cir-
cles). ΔCt values were obtained by subtracting the mean Ct value of β2-microglobin from the mean Ct value of each respective 
gene. Ct values for each gene were determined from triplicate reactions. Horizontal lines indicate ΔCt threshold values (3 
standard deviations from the mean). The ΔCt threshold for each gene are as follows: Peripheral blood: mam 24.00, PIP 24.19, 
CEA 21.93, PSE 15.28, CK19 6.32, muc1 7.57, EpCAM 15.49; Bone marrow: mam 22.00, PIP 18.32, CEA 12.64, PSE 12.48, CK19 
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BMC Cancer 2008, 8:55 http://www.biomedcentral.com/1471-2407/8/55PCR data (Chi-Square 0.1064; Fisher's exact test 0.1607;
ICC inconclusive results excluded).
Discussion
This paper describes molecular analyses of PBL and BM
samples from a subgroup of breast cancer patients who
were enrolled into a prospective multi-institutional study
with the primary goal to establish the clinical relevance of
micrometastatic disease detected by RT-PCR in pathology
negative axillary lymph nodes. Our previous reports from
this study strongly suggest that over-expression of cancer-
associated gene-marker is a valid surrogate for occult
micrometastatic breast cancer [33,34]. Using these gene
markers [mam, CEA, CK19, PIP, muc1, PSE, Erb (BM only)
and EpCAM (PBL only)] we analyzed 215 PBL samples
and 177 BM samples from patients with T1-T3 primary
breast cancer without clinical evidence of metastatic dis-
ease.
Using a predetermined rigorous threshold level (three
standard deviations from the mean expression in normal
PBL), 136 patients out of 215 (63.3%) had a positive sig-
nal in at least one cancer-associated marker in their PBL
sample. According to the other studies, the incidence of
CTC in PBL detected by RT-PCR ranged from 5% to 62%
for one-marker analyses [13,15,16,19-24,26-29] and from
31% to 83% for analyses by multi-marker gene-panels
[25-29]. The most frequently used markers were CK19 and
mam. Our study, in contradiction, suggested that CK19
has high expression level in normal control samples and
Table 2: Positivity of cancer-associated genes in peripheral blood and bone marrow specimens
PBLN (n = 49)
Ave. ΔCt (S.Dev.)
PBLBRCA (n = 215)
Positivity* (%)
BMN (n = 49)
Ave. ΔCt (S.Dev.)
BMBRCA (n = 177)
Positivity* (%)
Mam 24.00 (0.00) 29 (13.5%) 22.00 (0.00) 7 (4.0%)
PIP 25.84 (0.55) 36 (16.7%) 22.43 (1.37) 5 (2.8%)
CEA 23.88 (0.65) 51 (23.7%) 21.16 (2.84) 2 (1.1%)
PSE 22.60 (2.44) 58 (27.0%) 16.98 (1.50) 5 (2.8%)
CK19 21.41 (5.03) 0 (0%) 15.53 (5.11) 0 (0%)
Muc1 13.90 (2.11) 0 (0%) 6.77 (1.12) 0 (0%)
ErbB2 - - 8.91 (2.38) 0 (0%)
EpCAM 21.40 (1.97) 7 (3.3%) - -
Gene panel - 136 (63.3%) - 19 (10.7%)
* ΔCt threshold was set 3 standard deviations from the mean in normal samples
Table 3: Association of molecular positivity in peripheral blood of breast cancer patients with traditional predictors of prognosis.
Characteristic 5-gene panel (n = 136) mam (n = 29) PSE (n = 58)
Histologic Grade
I 31/63 (49.2%) 3/63 (4.8%) 15/63 (23.8%)
II-III 98/143 (68.5%) 22/143 (15.4%) 42/143 (29.4%)
P = 0.0083 P = 0.0315 P = 0.4110
Nodal Metastases (Path)
N0 97/150 (64.7%) 18/150 (12.0%) 46/150 (30.7%)
N1 37/64 (57.8%) 10/64 (15.6%) 12/64 (18.8%)
P = 0.3427 0.4715 P = 0.0726
ER Status
ER-neg 28/46 (60.9%) 10/46 (21.7%) 6/46 (13.0%)
ER-pos 98/154 (63.6%) 17/154 (11.0%) 49/154 (31.8%)
P = 0.7331 P = 0.0624 P = 0.0123
PR Status
PR-neg 40/67 (59.7%) 11/67 (16.4%) 12/67 (17.9%)
PR-pos 79/120 (65.8%) 16/120 (13.3%) 42/120 (35.0%)
P = 0.4033 P = 0.5650 P = 0.0134
Risk Category
Low/Intermediate Risk 20/34 (58.8%) 2/34 (5.9%) 9/34 (26.5%)
High Risk 116/181 (64.1%) 27/181 (14.9%) 49/181 (27.1%)
P = 0.5861 P = 0.2698* P = 0.9564
P-values obtained by Chi-square analysis or *Fisher's exact testPage 7 of 11
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CK19 primers were designed to avoid the amplification of
CK19 pseudogenes [40], we recognize that we cannot
entirely exclude this possibility. In addition, we are aware
of the limitations of using Ficoll density gradient cell sep-
aration methodology. Because of the low tumor cell bur-
den in PBL and BM, the accuracy of tumor cell detection
is greatly affected by the gene background expression lev-
els. The genes like CK19, muc1, PSE and EpCAM that show
significant background expression in normal samples,
loose its accuracy in tumor cell detection when Ficoll den-
sity gradient cell separation methodology is used. In fact,
in a separate publication we have demonstrated that using
OncoQuick tumor cell enrichment method significantly
reduces the background gene expression and therefore
increases the sensitivity of tumor cell detection compared
to the methodology employing Ficoll density gradi-
ent[27].
The mam gene on the other hand, because of its exquisite
tissue specificity, did not show any expression in normal
PBL. We observed a positive mam signal in 29 (13.5%)
patients, which is comparable to studies by Roncella et al
[20] and Benoy et al [13] who reported mam positivity in
12% (16/137) and 14% (16/116; M0) of patients, respec-
tively. Other studies have showed mam-based CTC detec-
tion ranging from 41% to 62% [24,26,28,29].
Positivity thresholds for cancer-associated gene-expres-
sion in BM were also set at three standard deviations from
the mean in normal BM. Based on this cut-off, 19 patients
out of 177 (10.7%) were positive by RT-PCR. All 19 sam-
ples were positive for one cancer-associated marker. Addi-
tionally, in a subgroup of 83 BM samples analyzed by
ICC, five (6%) resulted in a positive staining for cytokerat-
ins. Two out of these five samples were also positive by
RT-PCR (one for mam and another for PIP). Reports from
other investigators on the incidence of DTC in BM
detected by RT-PCR ranged from 12% to 53% [4,12-18]
and as high as 80% [6] in metastatic disease. DTC detec-
tion by ICC for cytokeratins ranged from 13.2% to 62%
(review by Braun et al [1]; [6]). In comparison to these
reports the detection of DTC in our study appears to be
relatively low. Although our study population contained
mainly early stage breast cancer patients (55% in Stage I,
27% in Stage IIA,14% in Stage IIB and 5% in Stage IIIA),
we also suspect that the limited volume of bone marrow
(average of 3–4 ml) in combination of Ficoll density gra-
dient methodology may not have been sufficient to
achieve optimal sensitivity.
One of our goals in this study was to evaluate whether the
expression of any individual gene was associated with
poor prognostic indicators. Although the follow-up data
for the breast cancer patients in this study is not yet avail-
able, we looked at the possible association of the detec-
tion of CTC and DTC with traditional clinicopathologic
prognostic indicators employing Chi-Square and/or
Fisher's exact tests. Among tumor size, histologic grade,
ER-, PR-, Her2neu-status, lymph node status and high risk
category, we observed a statistically significant association
between marker positivity in PBL and histologic grade
(grade II-III vs. grade I; p = 0.0083). There were no associ-
ations between marker positivity in PBL and pathologic
(H&E) and/or molecular (multi-marker RT-PCR) status of
axillary lymph nodes. Interestingly, overexpression of the
mammaglobin gene alone had also statistically significant
association with high grade (p = 0.0315) and showed a
trend towards ER-negative tumors (22% vs. 11%) and a
high risk category (15% vs. 6%), suggesting that mam gene
may be a poor prognostic indicator (Table 3). Although
we are not aware of other studies showing similar results
on mam, there are reports of statistically significant associ-
ation between mam-based CTC detection and tumor size
Table 4: Comparison between molecular analysis of peripheral blood (PBL) and molecular analysis of bone marrow (BM).
Gene panel Mam PIP
PBL(+)BM(+) 13 5 3
PBL(+)BM(-) 5 2 2
PBL(-)BM(+) 69 11 16
PBL(-)BM(-) 51 120 117
P-value P = 0.2356 P = 0.0002* P = 0.0188*
Concordance (%) 64/138 (46.4%) 125/138 (90.6%) 120/138 (87.0%)
P-values obtained by Chi-square analysis or *Fisher's exact test
Table 5: Comparison between immunocytochemistry (ICC) and 
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metastases [42-44] supporting the concept of mam gene
being a poor prognostic indicator.
In our study, marker positivity in BM had no statistically
significant association with any of the traditional prog-
nostic indicators, however, the results of mam and PIP
gene expression in PBL had statistically significant associ-
ation with the mam and PIP gene expression in BM (p =
2.5E-04 and p = 0.0188, respectively; Table 4). We suggest
that this result shows the close connection of PBL and BM
compartments and that mam and PIP overexpression is
not random but truly indicate the presence of tumor cells.
Overall concordance between PBL and BM results were
90.6% for mam and 87.0% for PIP, which is mainly due to
the concordance of double negative findings. Concord-
ance for gene-panel was 46.4%. In comparison, Benoy et
al demonstrated 68% of concordance between PBL and
BM samples using CK19 and 75% concordance between
PBL and BM samples using mam gene [13].
Clinical relevance of CTC in PBL and DTC in BM can only
be studied with sufficient follow-up data. The most com-
prehensive study has been reported on detection of bone
marrow micometastases published by Braun et al in the
New England Journal of Medicine [1]. They performed a
pooled analysis of a total of nine separate studies involv-
ing more than 4,500 breast cancer patients. Braun et al
concluded that patients with BM micrometastases had
poor overall survival (OS), breast-cancer-specific survival
and poor disease-free survival (DFS) and distant-disease-
free survival. A prospective, multi-center study by Cristo-
fanilli et al used a new CellSearch System (Veridex) to
determine if circulating tumor cells can predict survival in
metastatic breast cancer. They tested 177 patients and
found that patients with 5 or more tumor cells per 7.5 ml
before the therapy and at the first follow-up visit had
shorter median progression-free survival and OS com-
pared to the patients with fewer than 5 circulating cells
[30]. Benoy et al (CK19PCR, mamPCR) showed worse OS in
patients with CK19 and mam expression in BM but not in
PBL [13]. Median OS was reported to be shorter in
patients with CKICC positive cells in PBL according to Bau-
ernhofer et al [9]. Detection of CK19 positive cells by RT-
PCR in PBL in stage I and II was associated with reduced
disease-free interval and OS [45].
Conclusion
The interim results from this prospective clinical trial pro-
vides the first report of a statistically significant associa-
tion between detection of mam mRNA in PBL and high
grade breast tumors. Whether this result carries a clinical
significance will be seen after the completion of the 5-year
follow-up for this study.
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